Kryptos Biotechnologies, Inc. announced that it will receive $27,095,306.81 in a round of funding on March 18, 2024. The company will issue 7,315,181 series A-1 preferred shares at issue price of $3.1721 per share for the gross proceeds $23,204,485.6501; 902,831 series A-2 preferred shares at issue price of $2.268 per share for the gross proceeds $2,047,620.708; 375,100 series A-3 preferred shares at issue price of $2.898 per share for the gross proceeds $1,087,039.8; and 400,085 series A-4 preferred shares at issue price of $1.89 per share for the gross proceeds $756,160.65. The shares are convertible, non-redeemable and non-cumulative.

The shares carry cumulative dividend value of $0.222; $0.1588; $0.2029; and $0.1323 per annum per share respectively. The shares will be convertible in common shares at a price of $3.1721; $2.268; $2.898; and $1.89 per share respectively. The round will be raised at post money valuation of $37,842,630.